Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00127270 · ClinicalTrials.gov registry record · Phase 4
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 395
- Enrollment target
NCT00127270 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 395 participants.
The verdict
NCT00127270, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 395 participants
- Enrollment target
Study Summary
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
Interventions
- DRUG Darifenacin
- BEHAVIORAL Behavioral therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00127270
The ClinicalTrials.gov registry entry for NCT00127270 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 395 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Darifenacin is the first listed.
NCT00127270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00127270 about?
NCT00127270 is a clinical study titled "Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder". This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
What is the current status of trial NCT00127270?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 395 participants. The study started on 2005-05. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00127270?
The interventions under investigation include: Darifenacin (DRUG), Behavioral therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00127270?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.